Facebook Twitter LinkedIn Instagram Email Printer Google Plus

COVID-19

Rapid Cost Transformation to Establish a Baseline

Sixty-five percent of health plans with total membership in group commercial are at high-risk for negative profitability.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman
Partner, Financial Services, Oliver Wyman
Senior Consultant, Oliver Wyman

Executives discuss the COVID-19 financial fallout and what future subsequent peaks might look like for health systems.

Market dynamics are ripe for M&A activity. But before being enticed by a mirage, leaders must revisit old lessons.

Principal, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman

Social distancing may be necessary for two years or more. Here's where remote care comes into play.

Partner and Chief Medical Officer, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman

Health plans must maintain a competitive portfolio and double-down on their offerings.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman
Senior Consultant, Oliver Wyman
Principal, FSA, MAAA, Oliver Wyman

Insights in your inbox

Subscribe

Cost Transformation Amidst Uncertainty

Establish and aim towards a North Star to ensure your organization heads in the direction you want it to.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman
Senior Consultant, Oliver Wyman

An overview of mix shift modeling, including varying recovery scenarios, margin impact, and possible future legislation.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman
Senior Consultant, Oliver Wyman

Part 3: One Size Does Not Fit All

A closer look at unemployment, member migration, and financial impact amidst an ever-changing pandemic.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman
Senior Consultant, Oliver Wyman

Considerations for the pricing of health insurance products amidst a global crisis.

Partner, Health & Life Sciences, Oliver Wyman
Senior Advisor, Health & Life Sciences, Oliver Wyman

Part 2: Healthcare’s ‘Corona Effect’

Ten expectations regarding voluntary offerings, telemedicine, direct contracting, and more as COVID-19 unfolds.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe